{
      "ptx_code": "PTX155",
      "chem_name": "Clarithromycin",
      "casrn": "81103-11-9",
      "dtxsid": "DTXSID3022829",
      "smiles": "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC",
      "inchikey": "AGOYDEPGAOXOCK-KCBOHYOISA-N",
      "label": "PTX155 | Clarithromycin",
      "pubchem_cid": "84029",
      "drugbank_id": "DB01211",
      "use_class": "Pharmaceutical",
      "tox_class": "Hepatotoxicity; Ototoxicity; Cardiotoxicity",
      "formula": "C38H69NO13",
      "chem_name_user": "Clarithromycin",
      "mw_g_mol": "747.96",
      "solubility_h2o_mol_liter": "1.02e-03",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "9.48e-11",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "8.41",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "12.70;13.26;13.94;15.21",
      "pka_base": "8.55",
      "source_pka": "ACD pKa/GALAS",
      "log_kow_liter_liter": "3.16",
      "source_kow": "",
      "log_dlipw_ph74_liter_liter": "0.86",
      "source_dlipw": "LSER",
      "freely_dissolved_fraction": "0.90",
      "density_kg_liter": "",
      "source_density": "COMPTOX",
      "boiling_point": "433.0; 542.703; 805.478",
      "source_boiling_point": "CompTox, predicted (OPERA 2.6; TEST; ACD/Labs)",
      "melting_point": "112.492; 144.0",
      "source_melting_point": "CompTox, predicted (TEST; OPERA 2.6)",
      "vapor_pressure": "5.06e-30; 2.09411e-15; 8.511380382023759e-11",
      "source_vapor_pressure": "CompTox, predicted (ACD/Labs; TEST; OPERA 2.6)",
      "baseline_drerio": "23329.25",
      "baseline_dmagna": "6541.86",
      "baseline_celegans": "14081.03",
      "baseline_xlaevis": "2283.35",
      "baseline_dmelanogaster": "59108.19",
      "baseline_cells": "5.80e-03",
      "baseline_cells_generic_micromole_liter_free_ec10": "5.24e-03",
      "moa_drugbank": "Clarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump.",
      "protein_binding": "~ 70% protein bound",
      "moa_t3db": "",
      "aop": [],
      "targets": []
}